Himanshu Aggarwal: Low Dose Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
Himanshu Aggarwal, Biostatistician at Christian Medical College and Hospital, shared a post on LinkedIn:
“Exciting Publication Alert!
I am absolutely thrilled to share our latest research, just published in Blood Advances: ‘Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: A Non-Inferiority Trial.’
As the biostatistician on this study, working on a non-inferiority trial design was an incredibly rewarding challenge.
Statistically proving that a lower dose (1 mg/kg/d) is non-inferior to the standard dose (2 mg/kg/d) required careful sample size planning, strict non-inferiority margins, and rigorous data analysis.
But beyond the numbers and confidence intervals is a real-world impact for patients with Transfusion-Dependent Thalassemia (TDT).
By establishing that a lower dose is just as effective, we provide a data-driven path to reduce the burden of drug toxicity and side effects without compromising on the clinical benefits!
A massive thank you to Shruti Kakkar for her phenomenal clinical leadership, vision, and for trusting me to drive the statistical strategy.
It is always a privilege to collaborate with a principal investigator who truly values the synergy between clinical medicine and biostatistics.
Huge congratulations to the rest of our amazing co-authors and the entire clinical team for bringing this crucial trial to life!
When clinical expertise and rigorous statistics come together, patient care improves.”
Title: Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: A Non-Inferiority Trial
Authors: Shruti Kakkar, Amita Mahajan, Ratna Ajay Sharma, Nita Radhakrishnan, Mamta Manglani, Priyanka Dewan, Seema Dua, Manish Kumar Goel, Nupur Parakh, Himanshu Aggarwal, Varinder Singh, J S Arora, Sr., Jagdish Chandra
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 14:16Hyperfibrinolysis as an Underrecognized Cause of Bleeding
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval